Update shared on 05 Nov 2025
Fair value Decreased 0.78%Analysts have lowered their price target for Prestige Consumer Healthcare slightly, from $80.80 to $80.17. They cite a modest reduction in projected revenue growth, even though profitability metrics remain stable.
What's in the News
- Prestige Consumer Healthcare completed a share buyback tranche, repurchasing 410,446 shares for $34.67 million from April 1, 2025 to June 30, 2025. In total, 1,148,118 shares have been repurchased for $86.18 million under the current buyback program. (Key Developments)
- The company lowered its earnings guidance for fiscal year 2026, now expecting revenue between $1,100 million and $1,115 million, and diluted EPS between $4.50 and $4.58. This represents a decrease from previous forecasts. (Key Developments)
- Management affirmed ongoing efforts to pursue mergers and acquisitions. The company highlighted approximately $1 billion in expected free cash flow over the next four years as a potential driver for future value creation. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has declined modestly from $80.80 to $80.17 per share.
- Discount Rate remains unchanged at 6.78%.
- Revenue Growth projection has decreased from 1.00% to 0.96%.
- Net Profit Margin is virtually steady, with a slight increase from 20.47% to 20.49%.
- Future P/E Ratio has declined marginally from 20.0x to 19.8x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.